This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.'s Board Of Directors For Possible Breaches Of Fiduciary Duty

BOSTON, Dec. 16, 2011 /PRNewswire/ -- Block & Leviton LLP is investigating whether the Board of Directors of ISTA Pharmaceuticals, Inc. ("ISTA" or the "Company") (NASDAQ: ISTA) breached their fiduciary duties by rejecting an offer from Valeant Pharmaceuticals International, Inc. ("Valeant") (NASDAQ: VRX) to acquire the Company in a proposed transaction valued at $327 million

The investigation centers on whether ISTA's Board of Directors protected shareholder interests, and properly maximized shareholder value, when it refused Valeant's offer to acquire the Company for approximately $6.50 per share, representing a hefty premium to ISTA's shareholders of approximately 67% over the stock's closing price of $3.89 on December 15, 2011. 

If you own stock in ISTA and want to discuss your rights with regard to ISTA's rejection of the Valeant offer, or if you have any questions, please contact Mark Alan Delaney at (617) 398-5650 or

The attorneys at Block & Leviton LLP have more than 40 years of experience in representing individual and institutional investors in shareholder rights actions and throughout their careers have achieved significant recoveries for their clients.

This may constitute attorney advertising.

SOURCE Block & Leviton LLP
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs